Shilpa Medicare has launched a new full service ‘hybrid’ CDMO, which will see Shilpa serve both small and large molecules customers as well as peptides, with oncology as a particular therapeutic specialty. In addition to offering comprehensive discovery, clinical, and commercial outsourcing services, Shilpa’s hybrid CDMO model also includes commercially ready ‘off-the-shelf’ novel formulations for exclusive b2b licensing. This dual approach enables pharmaceutical companies to leverage S...